10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Goat Anti-CYP26A1 Antibody (internal region)

Purified Goat Polyclonal Antibody
Catalog # AF4156a

Specification

Goat Anti-CYP26A1 Antibody (internal region) - Product Information

Application	**IF**
Primary Accession	O43174
Other Accession	NP_000774.2, NP_476498.1
Reactivity	**Human**
Predicted	**Human**
Host	**Goat**
Clonality	**Polyclonal**
Concentration	**0.5**
Calculated MW	**56199**

Goat Anti-CYP26A1 Antibody (internal region) - Additional Information

Gene ID 1592

Other Names
CYP26A1; cytochrome P450, family 26, subfamily A, polypeptide 1; CP26; CYP26; P450RAI; P450RAI1; P450, retinoic acid-inactivating, 1; cytochrome P450, subfamily XXVIA, polypeptide 1; retinoic acid 4-hydroxylase; retinoic acid-metabolizing cytochrome

Format
Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20°C. Minimize freezing and thawing.

Immunogen
Peptide with sequence C-NLPARFTHFHGE, from the internal region of the protein sequence according to NP_000774.2; NP_476498.1.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
Goat Anti-CYP26A1 Antibody (internal region) is for research use only and not for use in diagnostic or therapeutic procedures.

Goat Anti-CYP26A1 Antibody (internal region) - Protein Information

Name CYP26A1 {ECO:0000303|PubMed:26937021, ECO:0000312|HGNC:HGNC:2603}

Function
A cytochrome P450 monooxygenase involved in the metabolism of retinoates (RAs), the active

metabolites of vitamin A, and critical signaling molecules in animals (PubMed:22020119, PubMed:9228017, PubMed:9716180). RAs exist as at least four different isomers: all- trans-RA (atRA), 9-cis-RA, 13-cis-RA, and 9,13-dicis-RA, where atRA is considered to be the biologically active isomer, although 9-cis-RA and 13-cis-RA also have activity (Probable). Catalyzes the hydroxylation of atRA primarily at C-4 and C-18, thereby contributing to the regulation of atRA homeostasis and signaling (PubMed:22020119, PubMed:9228017, PubMed:9716180). Hydroxylation of atRA limits its biological activity and initiates a degradative process leading to its eventual elimination (Probable). Involved in the convertion of atRA to all-trans-4-oxo-RA. Able to metabolize other RAs such as 9-cis, 13-cis and 9,13-di-cis RA (By similarity) (PubMed:9228017). Can oxidize all-trans-13,14- dihydroretinoate (DRA) to metabolites which could include all-trans-4- oxo-DRA, all-trans-4-hydroxy-DRA, all-trans-5,8-epoxy-DRA, and all- trans-18-hydroxy-DRA (By similarity). May play a role in the oxidative metabolism of xenobiotics such as tazarotenic acid (PubMed:26937021).

Cellular Location
Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein

Tissue Location
Expressed in most fetal and adult tissues with highest levels in adult liver, heart, pituitary gland, adrenal gland, placenta and regions of the brain (PubMed:9826557). Expressed at high levels in lung, pancreas, skin and uterus (at protein level) (PubMed:22020119). Lower expression level is detected in spleen, kidney, intestine and adipose tissue (at protein level) (PubMed:22020119).


Goat Anti-CYP26A1 Antibody (internal region) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Goat Anti-CYP26A1 Antibody (internal region) - Images

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



AF4156a (2.5 µg/ml) staining of PFA-fixed and TX100-treated HeLa cells after primary labelling overnight at 4C with DAPI nuclear counterstaining in blue.

Goat Anti-CYP26A1 Antibody (internal region) - References

Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents Patel JB, Khandelwal A, Chopra P, Handratta VD, Njar VC Cancer Chemother Pharmacol. 2007 Nov;60(6):899-905